MediciNova, Inc. (MNOV) AI Stock Analysis

MediciNova, Inc. is a biopharmaceutical company focused on developing small molecule therapeutics for serious diseases with unmet medical needs. Its pipeline includes MN-166 (ibudilast) for neurological disorders such as progressive multiple sclerosis, amyotrophic lateral sclerosis, and glioblastoma. The company is also developing MN-221 (bedoradrine) for acute exacerbations of asthma, MN-001 (tipelukast) for fibrotic conditions like nonalcoholic steatohepatitis and idiopathic pulmonary fibrosis, and MN-029 (denibulin) for solid tumors. Headquartered in La Jolla, California, MediciNova maintains collaboration agreements with partners such as Kissei Pharmaceutical Co., Ltd. and Kyorin Pharmaceutical Co., Ltd.

MediciNova generated revenue of $409,657 in FY2025, down 59.0% from $1.0M in FY2023 and well below $4.0M recorded in FY2020. Across the period from FY2020 to FY2025, revenue posted a three-year CAGR of -53.2%. The company reported net losses across all shown years, recording -$13.9M in FY2020, -$10.1M in FY2021, -$8.6M in FY2023, and -$12.0M in FY2025, alongside an FY2025 operating margin of -3242.5%. Research and development expense totaled $7.2M in FY2025. Over the trailing twelve months ending June 30, 2026, revenue stood at $920,481 with an operating margin of -554.3% and diluted EPS of -$0.21, while quarterly revenue rose 240.6% year-over-year.

As of June 30, 2026, MediciNova held $25.4M in cash and short-term investments against total debt of $117,038, resulting in net cash of $25.3M. Total assets stood at $40.4M, with shareholders' equity of $37.3M and a debt-to-equity ratio of 0.00. Liquidity is supported by a current ratio of 8.75. In FY2025, operating cash flow was -$9.8M, matching free cash flow of -$9.8M. Capital expenditures were $2,899, while the five-year share count increased by 0.5%.

At a last close of $1.42, MediciNova has a market capitalization of $69.9M and an enterprise value of $111.5M. The stock trades at a price-to-sales multiple of 75.9x, well above the median of 4.1x for its US-listed Healthcare peers. Its EV-to-revenue multiple is 121.2x, while forward P/E stands at 8.5x compared to the peer median of 17.3x. Price-to-book is 3.7x. Over the past year, MNOV returned 13.6%, trailing the S&P 500 (SPY) return of 16.8%, and over five years the stock fell 62.8% while the index gained 83.0%.

Wall Street coverage includes 3 Strong Buy ratings and 1 Buy rating, with no Hold, Sell, or Strong Sell recommendations. The mean price target is $8.25, representing an implied premium of 481.0% over the last close of $1.42. For the fiscal year ending December 31, 2026, analysts expect revenue of $730,000 and EPS of -$0.26. MediciNova beat EPS estimates in each of the last 4 quarters, and its next earnings report is scheduled for November 11, 2026.

This page is an AI-written research summary of MediciNova, Inc. (MNOV). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: MNOV income statement, MNOV balance sheet, MNOV key metrics, MNOV analyst forecast, MNOV chart. See the MNOV stock overview for the latest quote and news.